Extended treatment of Cushing's disease with pasireotide: Results from a 2-year, Phase II study

Pituitary

Volumn 17, Issue 4, 2014, Pages 320-326

  Boscaro, M ^a   Bertherat, J ^b,c,d   Findling, J ^e   Fleseriu, M ^f   Atkinson, A B ^g   Petersenn, S ^h   Schopohl, J ⁱ   Snyder, P ^j   Hughes, G ^k   Trovato, A ^k   Hu, K ^k   Maldonado, M ^k   Biller, B M K ^l  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INSTITUT COCHIN   (France)

^c Reference Centre for Rare Adrenal Diseases Department of Endocrinology Hôpital Cochin ^*  (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g ROYAL VICTORIA HOSPITAL   (United Kingdom)

^h ENDOC Center for Endocrine Tumors   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Clinical trial; Cushing's disease; Pasireotide; SOM230; Somatostatin analogue

Indexed keywords

CORTICOTROPIN; EXENDIN 4; GAMMA GLUTAMYLTRANSFERASE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; METFORMIN; PASIREOTIDE; PIOGLITAZONE; SOMATOSTATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECG ABNORMALITY; EXTENDED TREATMENT; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LONG TERM CARE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; YOUNG ADULT;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; SOMATOSTATIN; YOUNG ADULT;

EID: 84904134106     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0503-3     Document Type: Article

References (21)

1. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454-2462 (Pubitemid 352008503)
2. Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632-642
3. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527-2533 (Pubitemid 36724418)
4. van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR (2007) Cushing's syndrome and bone mineral density: lowest Z scores in young patients. Neth J Med 65:137-141 (Pubitemid 46656851)
5. Toogood AA, Stewart PM (2008) Hypopituitarism: clinical features, diagnosis, and management. Endocrinol Metab Clin North Am 37:235-261
6. Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M (2010) Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 10:10
7. Novartis Pharmaceuticals (2012) Signifor prescribing information. Available at: http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/ product/pi/pdf/signifor.pdf. Last accessed Feb 2013
8. Corcept Therapeutics (2012) Korlym prescribing information. Available at: http://www.corcept.com/prescribinginfo.pdf. Last accessed Feb 2013
9. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716 (Pubitemid 34552506)
10. Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47 (Pubitemid 36223278)
11. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
12. National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf
13. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BMK (2012) A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 366:914-924
14. Libe R, Groussin L, Bertherat J (2012) Pasireotide in Cushing's disease. N Engl J Med 366:2134-2135
15. Pivonello R, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, on behalf of the Pasireotide B2305 Study Group (2011) Improvement in clinical signs and symptoms of Cushing's disease following 12 months' pasireotide therapy. Endocrine Abstracts 26:abst P284
16. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098 (Pubitemid 36877477)
17. Mercado M, Borges F, Bouterfa H, Chang T-C, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859-868 (Pubitemid 47024274)
18. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13:18-28
19. Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G, Colao A (2010) Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 92(Suppl 1):77-81
20. Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167:311-326
21. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2013) Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary. doi:10.1007/s11102-013- 0483-3 [Epub ahead of print]